MA43106A - Traitement de l'oligo-ovulation associée à la stéatose hepatique - Google Patents

Traitement de l'oligo-ovulation associée à la stéatose hepatique

Info

Publication number
MA43106A
MA43106A MA043106A MA43106A MA43106A MA 43106 A MA43106 A MA 43106A MA 043106 A MA043106 A MA 043106A MA 43106 A MA43106 A MA 43106A MA 43106 A MA43106 A MA 43106A
Authority
MA
Morocco
Prior art keywords
oligo
treatment
hepatic steatosis
ovulation
ovulation associated
Prior art date
Application number
MA043106A
Other languages
English (en)
Other versions
MA43106B1 (fr
Inventor
Zegher Francis De
Lourdes Ibáñez
Original Assignee
Sant Joan De Deu Hospital
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sant Joan De Deu Hospital, Univ Leuven Kath filed Critical Sant Joan De Deu Hospital
Publication of MA43106A publication Critical patent/MA43106A/fr
Publication of MA43106B1 publication Critical patent/MA43106B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA43106A 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique MA43106B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hépatique

Publications (2)

Publication Number Publication Date
MA43106A true MA43106A (fr) 2021-05-05
MA43106B1 MA43106B1 (fr) 2021-09-30

Family

ID=55130283

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale
MA43106A MA43106B1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale

Country Status (24)

Country Link
US (2) US20190060328A1 (fr)
EP (2) EP3368044B1 (fr)
JP (2) JP6999903B2 (fr)
KR (1) KR102608158B1 (fr)
CN (2) CN117379440A (fr)
AR (1) AR106505A1 (fr)
AU (1) AU2016344737C1 (fr)
BR (1) BR112018008496A2 (fr)
CA (1) CA3003076C (fr)
DK (1) DK3368044T3 (fr)
ES (1) ES2883282T3 (fr)
GB (1) GB201518979D0 (fr)
HU (1) HUE055778T2 (fr)
IL (1) IL258876B (fr)
LT (1) LT3368044T (fr)
MA (2) MA54412A (fr)
MX (2) MX384040B (fr)
PL (1) PL3368044T3 (fr)
RS (1) RS62764B1 (fr)
RU (1) RU2745606C2 (fr)
SI (1) SI3368044T1 (fr)
TW (1) TWI791420B (fr)
UY (1) UY36967A (fr)
WO (1) WO2017072243A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
CA3107945A1 (fr) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Formulation a liberation immediate d'une triple combinaison d'ingredients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques
EP3842803A1 (fr) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 dans le syndrome des ovaires polykystiques
IL298128A (en) 2020-05-13 2023-01-01 Akouos Inc Compositions and methods for treating slc26a4-associated hearing loss
AU2021391433A1 (en) 2020-12-01 2023-06-22 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
JP2024500786A (ja) 2020-12-29 2024-01-10 アコーオス インコーポレイテッド Ｃｌｒｎ１関連難聴及び／または視力低下を治療するための組成物及び方法
CA3243517A1 (fr) 2022-02-02 2023-08-10 Akouos, Inc. Constructions d'anticorps anti-vegf et méthodes connexes pour le traitement de symptômes associés au neurinome de l'acoustique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004052390A1 (fr) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methodes et compositions de traitement du syndrome stein-leventhal
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
CA3107945A1 (fr) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Formulation a liberation immediate d'une triple combinaison d'ingredients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques

Also Published As

Publication number Publication date
RU2745606C2 (ru) 2021-03-29
WO2017072243A8 (fr) 2018-03-22
RU2018119146A (ru) 2019-11-28
WO2017072243A9 (fr) 2018-07-26
MX2021007976A (es) 2021-08-16
IL258876B (en) 2022-03-01
RS62764B1 (sr) 2022-01-31
EP3892281A3 (fr) 2021-11-10
BR112018008496A2 (pt) 2018-10-23
UY36967A (es) 2017-05-31
JP6999903B2 (ja) 2022-02-04
EP3892281A2 (fr) 2021-10-13
US20190060328A1 (en) 2019-02-28
TWI791420B (zh) 2023-02-11
JP2019501113A (ja) 2019-01-17
US20240000804A1 (en) 2024-01-04
IL258876A (en) 2018-06-28
HUE055778T2 (hu) 2021-12-28
MA43106B1 (fr) 2021-09-30
ES2883282T3 (es) 2021-12-07
KR102608158B1 (ko) 2023-11-29
EP3368044B1 (fr) 2021-06-09
EP3368044A1 (fr) 2018-09-05
AU2016344737C1 (en) 2021-10-07
CN108778285A (zh) 2018-11-09
PL3368044T3 (pl) 2021-12-20
AU2016344737A1 (en) 2018-05-17
RU2018119146A3 (fr) 2020-02-25
JP2022009374A (ja) 2022-01-14
TW201720432A (zh) 2017-06-16
LT3368044T (lt) 2021-10-25
AU2016344737B2 (en) 2021-07-08
MX384040B (es) 2025-03-14
GB201518979D0 (en) 2015-12-09
SI3368044T1 (sl) 2022-05-31
DK3368044T3 (da) 2021-09-13
MX2018005252A (es) 2018-09-18
CA3003076C (fr) 2023-12-05
AU2016344737A9 (en) 2018-08-09
AR106505A1 (es) 2018-01-24
CN117379440A (zh) 2024-01-12
WO2017072243A1 (fr) 2017-05-04
KR20180098234A (ko) 2018-09-03
CA3003076A1 (fr) 2017-05-04
MA54412A (fr) 2021-11-10

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3464313A4 (fr) Nucléotides modifiés 5 '-cyclo-phosphonate
MA46180A (fr) Analogues de l'amyline
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
EP3360554A4 (fr) Agent anti-virus de l'hépatite b
EP3325963A4 (fr) Amélioration de l'estimation de globules
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
HRP20251450T1 (hr) Beta-d-2'-dezoksi-2'alfa-fluoro-2'-beta-c-supstituirani-2-modificirani-n6-supstituirani purinski nukleotidi za liječenje hcv
EP3261641A4 (fr) Traitement de la pancréatite
FR3036037B1 (fr) Harnais d'encordement perfectionne
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
MA47558A (fr) Traitement de la fibrose
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
EP3250367A4 (fr) Étalonnage d'agent
EP3375108A4 (fr) Traitement dewlan
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
LT3307267T (lt) Išsėtinės sklerozės gydymas
EP3347032A4 (fr) Traitement de l'ascite
DK3706699T3 (da) Badekonstruktion
EP3328384A4 (fr) Traitement de la fibrose
EP3309165A4 (fr) Agent de traitement de surface
MA41782A (fr) Traitement de patients atteints de diabète de type 2